Oral contraceptive tablets containing 20 and 30 μg of ethinyl estradiol with 150 μg desogestrel: Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone
- 1 February 1994
- journal article
- clinical trial
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 73 (2) , 136-143
- https://doi.org/10.3109/00016349409013416
Abstract
The effect of two oral contraceptive (OC) pills, both containing 150 micrograms of desogestrel, but with 20 (Mercilon) or 30 micrograms (Marvelon/Desolett) of ethinyl estradiol on plasma levels of lipids, lipoproteins and sex hormone binding globulin (SHBG), total and free testosterone were compared in a double-blind, randomized, two-center study in a total of 60 women over one year. A significant rise with Marvelon but not with Mercilon was seen in total cholesterol, HDL cholesterol, HDL-3 and apolipoprotein B, whereas LDL cholesterol decreased with Mercilon only. These effects resulted in significant differences between the two groups in the magnitude of responses in all these parameters except HDL-3. HDL-2, apolipoprotein A-1 and total phospholipids were elevated with both pills after treatment and with no difference in the degree of response between groups. The HDL/LDL cholesterol ratio tended to increase in both groups and that of apolipoproteins A-1/B in the women on Mercilon. Total triglycerides increased in both groups, but more in the women on Marvelon. Total testosterone decreased, particularly in the Marvelon group, whereas the two pills caused a similar increase in SHBG and decrease in free testosterone. It is concluded that the direction of changes in plasma lipids and lipoproteins with both these pills may as a whole be interpreted as beneficial, and that the differences in effect on LDL cholesterol and apolipoprotein B may suggest a slightly advantageous effect of Mercilon in this aspect. However, the clinical significance of these changes is uncertain. The results indicate a lack of androgenicity of both pills.Keywords
This publication has 35 references indexed in Scilit:
- Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case‐control studyBJOG: An International Journal of Obstetrics and Gynaecology, 1991
- Cardiovascular risks: New insights from FraminghamAmerican Heart Journal, 1988
- Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questionsAmerican Heart Journal, 1987
- Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham StudyAmerican Heart Journal, 1987
- Effects of the Oral Contraceptive Combination 0.150 mg Desogestrel+0.020 mg Ethinylestradiol on Serum Lipids, SHBG, Glycosylated Proteins and Plasma Antithrombin III Activity in Healthy WomenActa Obstetricia et Gynecologica Scandinavica, 1987
- Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogensThe Prostate, 1987
- Pharmacodynamic Studies on Desogestrel Administered Alone and in Combination with EthinylestradiolActa Obstetricia et Gynecologica Scandinavica, 1985
- On the use of Plasma Proteins as Indicators of the Metabolic Effects of Combined Oral ContraceptivesPublished by Wiley ,1982
- Oral Contraceptives and Cardiovascular DiseaseNew England Journal of Medicine, 1981
- A RANDOMIZED DOUBLE‐BLIND TRIAL OF TWO LOW DOSE COMBINED ORAL CONTRACEPTIVESBJOG: An International Journal of Obstetrics and Gynaecology, 1979